(CRH) CRH - Ratings and Ratios
Aggregates, Cement, Readymixed Concrete, Asphalt, Precast
Dividends
| Dividend Yield | 1.18% |
| Yield on Cost 5y | 3.93% |
| Yield CAGR 5y | 6.47% |
| Payout Consistency | 87.3% |
| Payout Ratio | 28.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 28.1% |
| Value at Risk 5%th | 44.8% |
| Relative Tail Risk | -3.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.97 |
| Alpha | 16.98 |
| CAGR/Max DD | 1.74 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.454 |
| Beta | 1.203 |
| Beta Downside | 1.215 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.01% |
| Mean DD | 5.39% |
| Median DD | 3.39% |
Description: CRH CRH December 03, 2025
CRH plc (NYSE:CRH) is an Ireland-based building-materials conglomerate that operates through three geographic segments-Americas Materials Solutions, Americas Building Solutions, and International Solutions-serving public infrastructure, commercial, and residential construction markets worldwide. Its product portfolio spans aggregates, cement, ready-mix concrete, asphalt, precast concrete, polymer-based systems, and a range of engineered anchoring and hard-scape solutions, enabling the company to capture value across the full construction value chain.
Key performance indicators from the most recent fiscal year (2023) show revenue of €30.5 bn, an adjusted EBITDA margin of roughly 12.5 %, and free cash flow conversion of 85 % of EBITDA, reflecting strong cash generation despite cyclical pressures. Capital expenditure was €1.2 bn, primarily directed toward expanding its U.S. ready-mix and precast platforms, which now represent about 45 % of total sales-a concentration that amplifies exposure to U.S. construction activity.
Sector drivers that materially affect CRH’s outlook include U.S. residential housing starts (which have risen 7 % YoY in Q3 2024), sovereign infrastructure spending plans (e.g., the EU’s €1.8 tn “NextGenerationEU” fund), and the trajectory of real-interest rates, which influence both private-sector building activity and public-sector project financing. A sustained upward trend in these macro variables would likely support CRH’s top-line growth, while a sharp rise in input costs (energy, raw materials) could compress margins.
For a data-rich, quantitative deep-dive on CRH’s valuation sensitivities and scenario analysis, the ValueRay platform offers tools that can help you model these dynamics more rigorously.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (3.21b TTM) > 0 and > 6% of Revenue (6% = 2.08b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.97% (prev 11.75%; Δ 1.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 5.28b > Net Income 3.21b (YES >=105%, WARN >=100%) |
| Net Debt (14.05b) to EBITDA (7.04b) ratio: 2.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (675.5m) change vs 12m ago -1.46% (target <= -2.0% for YES) |
| Gross Margin 36.12% (prev 35.27%; Δ 0.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 71.55% (prev 69.32%; Δ 2.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.04 (EBITDA TTM 7.04b / Interest Expense TTM 701.5m) >= 6 (WARN >= 3) |
Altman Z'' 3.44
| (A) 0.09 = (Total Current Assets 14.39b - Total Current Liabilities 9.90b) / Total Assets 49.97b |
| (B) 0.43 = Retained Earnings (Balance) 21.40b / Total Assets 49.97b |
| (C) 0.10 = EBIT TTM 4.94b / Avg Total Assets 48.34b |
| (D) 0.73 = Book Value of Equity 21.27b / Total Liabilities 28.94b |
| Total Rating: 3.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.24
| 1. Piotroski 7.0pt |
| 2. FCF Yield 2.56% |
| 3. FCF Margin 7.30% |
| 4. Debt/Equity 0.89 |
| 5. Debt/Ebitda 2.00 |
| 6. ROIC - WACC (= 1.25)% |
| 7. RoE 16.24% |
| 8. Rev. Trend -44.67% |
| 9. EPS Trend 8.75% |
What is the price of CRH shares?
Over the past week, the price has changed by -0.62%, over one month by +5.12%, over three months by +10.17% and over the past year by +38.07%.
Is CRH a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CRH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 139 | 10.5% |
| Analysts Target Price | 139 | 10.5% |
| ValueRay Target Price | 174.8 | 39% |
CRH Fundamental Data Overview December 27, 2025
P/E Trailing = 25.4571
P/E Forward = 20.9205
P/S = 2.3126
P/B = 3.661
P/EG = 2.2179
Beta = 1.195
Revenue TTM = 34.59b USD
EBIT TTM = 4.94b USD
EBITDA TTM = 7.04b USD
Long Term Debt = 14.73b USD (from longTermDebt, last quarter)
Short Term Debt = 3.69b USD (from shortTermDebt, last quarter)
Debt = 17.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.05b USD (from netDebt column, last quarter)
Enterprise Value = 98.77b USD (85.34b + Debt 17.63b - CCE 4.20b)
Interest Coverage Ratio = 7.04 (Ebit TTM 4.94b / Interest Expense TTM 701.5m)
FCF Yield = 2.56% (FCF TTM 2.53b / Enterprise Value 98.77b)
FCF Margin = 7.30% (FCF TTM 2.53b / Revenue TTM 34.59b)
Net Margin = 9.27% (Net Income TTM 3.21b / Revenue TTM 34.59b)
Gross Margin = 36.12% ((Revenue TTM 34.59b - Cost of Revenue TTM 22.09b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 39.45%)
Tobins Q-Ratio = 1.98 (Enterprise Value 98.77b / Total Assets 49.97b)
Interest Expense / Debt = 1.19% (Interest Expense 209.0m / Debt 17.63b)
Taxrate = 22.28% (428.0m / 1.92b)
NOPAT = 3.84b (EBIT 4.94b * (1 - 22.28%))
Current Ratio = 1.45 (Total Current Assets 14.39b / Total Current Liabilities 9.90b)
Debt / Equity = 0.89 (Debt 17.63b / totalStockholderEquity, last quarter 19.90b)
Debt / EBITDA = 2.00 (Net Debt 14.05b / EBITDA 7.04b)
Debt / FCF = 5.56 (Net Debt 14.05b / FCF TTM 2.53b)
Total Stockholder Equity = 19.74b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.41% (Net Income 3.21b / Total Assets 49.97b)
RoE = 16.24% (Net Income TTM 3.21b / Total Stockholder Equity 19.74b)
RoCE = 14.33% (EBIT 4.94b / Capital Employed (Equity 19.74b + L.T.Debt 14.73b))
RoIC = 10.07% (NOPAT 3.84b / Invested Capital 38.13b)
WACC = 8.82% (E(85.34b)/V(102.97b) * Re(10.45%) + D(17.63b)/V(102.97b) * Rd(1.19%) * (1-Tc(0.22)))
Discount Rate = 10.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 66.29% ; FCFE base≈2.39b ; Y1≈1.99b ; Y5≈1.47b
Fair Price DCF = 27.88 (DCF Value 18.65b / Shares Outstanding 669.1m; 5y FCF grow -20.07% → 3.0% )
EPS Correlation: 8.75 | EPS CAGR: -9.86% | SUE: 0.06 | # QB: 0
Revenue Correlation: -44.67 | Revenue CAGR: -8.21% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.18 | Chg30d=N/A | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=6.06 | Chg30d=+0.014 | Revisions Net=-4 | Growth EPS=+9.2% | Growth Revenue=+6.2%
Additional Sources for CRH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle